NEW YORK (GenomeWeb) – CRISPR Therapeutics and Neon Therapeutics said today that they have entered a research collaboration to explore using a combination of each company's proprietary technologies to develop novel T cell therapies.

Headquartered in Basel, Switzerland, CRISPR Therapeutics is a gene-editing company focused on developing gene-based medicines for serious diseases using a proprietary CRISPR/Cas9 gene-editing platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.